Navigation Links
Venaxis to Present at Piper Jaffray 25th Annual Healthcare Conference
Date:11/21/2013

anufacture and generate revenues from the APPY1 Test at a profitable price point, execute agreements required to successfully advance the company's objectives, retain the management team to advance the products, overcome adverse changes in market conditions and the regulatory environment, obtain and enforce intellectual property rights, and realize value of intangible assets. Furthermore, Venaxis does not intend (and is not obligated) to update publicly any forward-looking statements. The contents of this press release should be considered in conjunction with the risk factors contained in Venaxis' recent filings with the SEC, including its Form 10-Q for the quarter ended June 30, 2013.

Venaxis and APPY1 are trademarks of Venaxis, Inc.

For Investors and Media:
Tiberend Strategic Advisors, Inc.

Joshua Drumm, PhD
jdrumm@tiberend.com; (212) 375-2664

Claire Sojda
csojda@tiberend.com; (212) 375-2686


'/>"/>
SOURCE Venaxis, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Venaxis APPY1 Test Passes Futility Analysis in Pivotal Clinical Study
2. Venaxis Announces Pricing of Offering of Common Stock and Warrants
3. Venaxis Executes First Commercial Development Agreement and Receives Purchase Order from EMELCA Bioscience for Initial EU Launch
4. Dyadic International To Present At Two Major Conferences In December 2013
5. Sangamo BioSciences Announces Seven Data Presentations At The 2013 American Society of Hematology Annual Meeting
6. Aratana Therapeutics to Present at Two Upcoming Investor Conferences
7. Celladon Corporation Announces Oral Presentation at American Heart Association of Long Term Follow-Up Results from the MYDICAR CUPID 1 Trial in Advanced Heart Failure
8. Amgen Presents Interim Overall Survival Data From Phase 3 Study Of Talimogene Laherparepvec In Patients With Metastatic Melanoma
9. Accuray to Present at Piper Jaffray 25th Annual Healthcare Conference
10. Cartes 2013: DERMALOG Presents World Firsts in Biometrics
11. Proove Biosciences to Present Research on the Genetics of Pain Medicine and Exhibit at ASRA’s 12th Annual Pain Medicine Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... The next implants made from the PEEK-OPTIMA® ... (European) approval. The CE mark is necessary for distributing ... the European Union. Following the Class IIb approval route, ... supplied by the Turkey-based company Osimplant for the treatment ... Expandable Bladed HA PEEK Cage line of spinal implants, ...
(Date:3/4/2015)... , March 4, 2015 The UPMC Center ... 2015 Fellows in the Emerging Leaders in Biosecurity Initiative ... leaders in the field of biosecurity, UPMC has selected ... a wide array of backgrounds, including biological science, medicine, ... "With the vision and support of ...
(Date:3/4/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/jspg2c/global_biologics ) ... Biologics and Biosimilars Industry Report 2015" report ... Global Biologics and Biosimilars Industry Report 2015 is ... state of the biologics and biosimilars industry. ... the industry including definitions, classifications, applications and industry ...
(Date:3/4/2015)... 4, 2015 AcelRx Pharmaceuticals, Inc. (Nasdaq: ... focused on the development and commercialization of innovative ... pain, today announced that it will release fourth ... close on Monday, March 9th, 2015. AcelRx management ... p.m. Eastern Time (1:30 p.m. Pacific Time) on ...
Breaking Biology Technology:Invibio’s PEEK-OPTIMA® HA Enhanced Gains Momentum: New Implant Receives European Approval 2Invibio’s PEEK-OPTIMA® HA Enhanced Gains Momentum: New Implant Receives European Approval 3UPMC Center for Health Security Announces 2015 Emerging Leaders in Biosecurity 2UPMC Center for Health Security Announces 2015 Emerging Leaders in Biosecurity 3Global Biologics and Biosimilars Industry Report 2015-2020 2AcelRx Pharmaceuticals to Hold Annual 2014 Financial Results Conference Call and Webcast on Monday, March 9th, 2015 2AcelRx Pharmaceuticals to Hold Annual 2014 Financial Results Conference Call and Webcast on Monday, March 9th, 2015 3
... ZURICH, Switzerland, January 28 Nycomed has ... exclusive development, marketing and,commercialisation rights for Ciclesonide ... corticosteroid with a novel principle of action. ... Inhalation Aerosol for the,treatment of asthma and ...
... Better Option for Humans, EGG HARBOR TOWNSHIP, ... first time, The British Institute of Homeopathy, U.S.A. ... U.S. medical and,homeopathic practitioners for a low-introductory cost ... therapy is more advantageous because,it does not carry ...
... CINCINNATI, Jan. 28 Kendle (Nasdaq: KNDL ... that Chairman and Chief Executive Officer Candace Kendle, ... The conference,will be held at the Langham Hotel ... for Wednesday, Jan. 30 at 1:30 p.m. Eastern ...
Cached Biology Technology:Nycomed's Ciclesonide to be Commercialised in the United States by Sepracor 2Nycomed's Ciclesonide to be Commercialised in the United States by Sepracor 3Nycomed's Ciclesonide to be Commercialised in the United States by Sepracor 4Nycomed's Ciclesonide to be Commercialised in the United States by Sepracor 5Nycomed's Ciclesonide to be Commercialised in the United States by Sepracor 6Kendle to Present at the Wachovia 2008 Healthcare Conference 2
(Date:1/22/2015)... ( http://www.researchandmarkets.com/research/4trb7t/biometrics_a ) has announced the addition of ... to their offering. , The primary goal ... who she/he is claiming to be, and for this purpose, ... characteristics, such as fingerprint, hand or palm print, iris, face ...
(Date:1/22/2015)... /PRNewswire/ - Today, FindBiometrics, the leading source of biometrics industry news, ... website design. "When we launched FindBiometrics 12 years ... O,Neill , founder and CEO of FindBiometrics. "Now it,s maturing ... the key players on a very broad scale.  We are ...
(Date:1/22/2015)... 2015 Technology Showcase, Hall E -   EyeLock Inc. ... announced it will showcase its EyeLock ID technology integrated in ... of Energy,s Oak Ridge National Laboratory (ORNL) at ... iris identity authentication technology is being used to validate the ...
Breaking Biology News(10 mins):Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 3
... what looks to be a nice piece of certified sustainable ... what you,re getting. Unfortunately, things aren,t always what they seem, ... eco-labeled Chilean sea bass and report their findings in the ... Press publication. "We found that, for fish purchased ...
... population biologist Peter Marko and his colleagues have found that ... claimed to be. Some fish sold in stores are not ... not Chilean sea bass at all. The research by ... Aug. 23 edition of Current Biology (Marko et ...
... , This press release is available in ... (USDA) scientists working with the University of Illinois at ... reduce soybean yields by an average 23 percent. ... Agricultural Research Service Soybean/Maize Germplasm, Pathology, and Genetics Research ...
Cached Biology News:Eco-labeled seafood is not always what it seems 2Breeding ozone-tolerant crops 2
... CE-based system provides clear advantages over ... load, gene expression), mutation analysis, and ... system with microplate connectivity is ideal ... quality control. The P/ACE Series ...
The imaging screen-K (Kodak), is a 35 x 43 cm storage phosphor screen that is used for the quantitation and imaging of 32P, 33P, 35S, 14C, and 3H....
The filter 695RDF55 Reflect 635 for the Molecular Imager FX is a band pass filter for Cy5 and Alexa Fluor 635 dyes....
... Kit is a 2-color staining method for ... to detect apoptotic cells by flow cytometry. ... required for measuring apoptosis in cells, including ... reagent performance; washing, reaction and rinsing buffers ...
Biology Products: